Those persons who suffer with eye allergies or have trouble wearing contact lenses, or indeed those who wear contact lenses on a regular basis, should read the following report which charts the use of a German made eye drop/ bath called Conjunctisan B ®.
The basis of all VitOrgan products (the manufacturer of Conjunctisan) and indeed its founder Dr. H. Dyckerdorf, is that the body can be encouraged to repair and regenerate its tissues through the supplementation of natural RNA’s, vitamins, amino-acids, procaine etc. An article in the July 1996 bulletin (now in the 1996 compilation anti-aging bulletin- request one if required), covered Conjunctisan A ®. It is an eye drop containing natural eye lysates (of bovine origin) and macromolecular tissue extracts to help regenerate and repair the aged eye, which has an impressive 67% success rate in treating cataract and an even better success rate in preventing cataract.
Conjunctisan B ® is the sister product of Conjunctisan A ®, both of which has been used in Europe for over a decade with considerable efficacy and have no known side effects or contraindications.
Conjunctisan B ® differs slightly in its formulation as it is aimed at those who wear contact lenses or who have regular eye allergy problems.
Conjunctisan B ® how it counteracts lens cleaning fluids
For many years in Europe Conjunctisan B ® has been used successfully in ophthalmology, specifically for allergic disorders of the conjunctiva and cornea, for conjunctivitis sicca and for chorioiditis.
Tests conducted on the eyes of animals revealed a disturbing trait behind long term exposure to the cleaning fluid solutions commonly used for contact lenses. The therapeutic influence of Conjunctisan B ® on severe conjunctival inflammations and tissue damage caused by contact lens cleaning solutions was shown in a 24-month test on rabbits and pigs.
Figure One (pictures are in the bulletins) is the damaged eye that had been affected by the constant exposure to contact lens cleaning fluid.
Figure Two is the still slightly damaged eye of the animal after exposure to contact lens cleaning fluid had been stopped.
Figure Three is after treatment with Conjunctisan B ® this is the same time period as Figure Two. Clearly indicating that not only is the Conjunctisan B ® treatment able to help repair and regenerate the eye to a healthy condition but that actual normal repair processes are speeded up by at least 50%.
The unique macromolecular combination of Conjunctisan B ® also contains thymus extracts, an important contributor toward the strength of the immune system.
Conjunctisan B ® doesn’t contain any preservatives, this may seem an unusual thing to point out, but indeed many other eye treatments/ baths do contain preservatives and yet these may interfere with the very eye allergies they are supposed to be treating! As a result, Conjunctisan B ® doesn’t cause any allergic reactions; the unit-dose vial is a method of application, which allows a hygienic and sterile treatment with the organotherapeutic factors.
Stabilization of the lacrimal film and protection of the conjunctiva, caused by the substituting effectiveness of Conjunctisan B ®, was demonstrated in another study. More than 200 eyes with contact lens problems were examined and received basic therapy with Conjunctisan B ®. At the same times the therapeutic spectrum was examined with animal experiments.
A fundamental and permanent improvement in wearing contact lenses was achieved by applying Conjunctisan B ®.
Heavy eyestrains, irritations of the anterior segment of the eye and edemas of the cornea could be treated with Conjunctisan B ® and a permanent cure could be achieved.
Adaptation complaints and other spontaneous intolerance phenomena disappeared quickly with continued treatment of Conjunctisan B ®.
Conjunctisan B’s stimulation of interferon
Another interesting aspect of Conjunctisan B ® is its ability to stimulate interferon when inhaled nasally.
Interferon counteracts inflammatory processes and is effective as prophylaxis and therapy of starting viral disease.
Animal experiments have shown that when Conjunctisan B ® is applied intra-nasally 3 times every two hours that two hours after the last application a high level of interferon was already in the serum. After 6 hours a maximum titer of 1:1024 was achieved and after 24 hours the interferon level decreased. It has been suggested that this is a natural and safer way of increasing interferon levels, rather than introducing chemical interferon inducers. Inducers such as Poly I; Poly C. In fact Poly I; Poly C was only able to increase interferon levels to the same maximum titer as Conjunctisan B ® but decreased after only 6 hours.
Conjunctisan B’s doses and uses
Conjunctisan B ® is the choice therapeutic agent for contact lens problems, especially as a regenerative and reparative therapy of the anterior segment of the eye after permanent stress caused by contact lenses cleaning solutions.
Conjunctisan B ® makes wearing contact lenses more comfortable. After storage in cleaning solution, followed by rinsing, one should place the contact lenses into a vial of Conjunctisan B ® for 30 minutes before placing into the eye.
For general treatment of eye allergies, several drops should be placed into each eye as necessary, and the contents may be inhaled nasally if required. The vials should be stored in the fridge once opened and then used within a 48-hour period.
1. V Ardenne, M Krug, E Kugler. “Remarkable results with Revitorgan substances, more effective than the chemical defined substances.” Die Heilkunst 11, 492-500, 1984.
2. Fabian G. “Morphological method of representation of the lymph tract of the eye and its connection to the lymphatic system.” Therapiewoche 35/26A, 68-76, 1985.
3. Wanderak H. “Repair and regenerative therapy of the eye with Conjunctisan B ® after permanent stress caused by contact lens cleaning solutions.” Therapiewoche, 32, 2855-2860, 1982.
4. Wanderak H. “Stabilisation of lacrimal film and protection of the conjunctiva with Conjunctisan B ®.”
5. Mayr A “Gutachterliche Stellungnahme uber die Stimulierung von endogenem Interferon durch Conjunctisan B ®.” 1975